Source: Medpage Today
“SAN FRANCISCO — Four years of clinical data indicate that patients infected with human immunodeficiency virus and treated with the integrase inhibitor raltegravir (Isentress) fare as well as patients treated with efavirenz (Sustiva), researchers here reported.
“There is no difference between these patients in efficacy after [192 weeks], but the side effects on lipids favor raltegravir,” said Eduardo Gotuzzo, MD, director of infectious diseases at Hospital Nacionale Cayetano Heredia, in Lima, Peru.”
Click here to read more.
